Safety evaluation of the food enzyme lysophospholipase from *Trichoderma reesei* (strain RF7206)

EFSA Panel on Food Contact Materials, Enzymes and Processing Aids (CEP), Vittorio Silano, José Manuel Barat Baviera, Claudia Bolognesi, Beat Johannes Bruschweiler, Pier Sandro Cocconcelli, Riccardo Crebelli, David Michael Gott, Konrad Grob, Evgenia Lampi, Alicja Mortensen, Gilles Riviere, Inger-Lise Steffensen, Christina Tlustos, Henk Van Loveren, Laurence Vernis, Holger Zorn, Boet Glandorf, Francesca Marcon*, Andrée Penninks*, Andrew Smith*, Ana Gomes, Natália Kovalková, Yi Liu, Joaquim Maia, Karl Heinz Engel* and Andrew Chesson

**Abstract**

The food enzyme lysophospholipase (EC 3.1.1.5) is produced with the genetically modified *Trichoderma reesei* strain RF7206 by AB Enzymes GmbH. The genetic modifications do not give rise to safety concerns. The food enzyme is free from viable cells of the production organism and recombinant DNA. The lysophospholipase food enzyme is intended to be used in starch processing for the production of glucose syrups. Residual amounts of total organic solids (TOS) are removed by the purification steps applied during the production of glucose syrups, consequently, dietary exposure was not calculated. Genotoxicity tests did not raise a safety concern. The systemic toxicity was assessed by means of a repeated dose 90-day oral toxicity study in rats. The Panel identified a no observed adverse effect level at the highest dose tested of 927 mg TOS/kg body weight (bw) per day. Similarity of the amino acid sequence to those of known allergens was searched and no match was found. The Panel considered that, under the intended condition of use, the risk of allergic sensitisation and elicitation reactions upon dietary exposure to this food enzyme cannot be excluded, but the likelihood of such reactions to occur is considered to be low. Based on the data provided and the removal of TOS during the intended food production process, the Panel concluded that this food enzyme does not raise safety concerns under the intended conditions of use.

© 2019 European Food Safety Authority. *EFSA Journal* published by John Wiley and Sons Ltd on behalf of European Food Safety Authority.

**Keywords:** food enzyme, lysophospholipase, lecithinase B, EC 3.1.1.5, Lysolecithinase, *Trichoderma reesei*, genetically modified microorganism

**Requestor:** European Commission

**Question number:** EFSA-Q-2015-00410

**Correspondence:** fip@efs.europa.eu

* Member of the Working Group on Enzymes of the EFSA Panel Food Contact Materials, Enzymes, Flavourings and Processing Aids (CEF) until 3-7-2018.
Panel members: José Manuel Barat Baviera, Claudia Bolognesi, Beat Johannes Brüschweiler, Andrew Chesson, Pier Sandro Cocconcelli, Riccardo Crebelli, David Michael Gott, Konrad Grob, Evgenia Lampi, Alicja Mortensen, Gilles Riviere, Vittorio Silano, Inger-Lise Steffensen, Christina Tlustos, Henk Van Loveren, Laurence Vernis and Holger Zorn.

Note: The full opinion will be published in accordance with Article 12 of Regulation (EC) No 1331/2008 once decision on confidentiality will be received from the European Commission.

Suggested citation: EFSA CEP Panel (EFSA Panel on Food Contact Materials, Enzymes and Processing Aids), Silano V, Barat Baviera JM, Bolognesi C, Brüschweiler BJ, Cocconcelli PS, Crebelli R, Gott DM, Grob K, Lampi E, Mortensen A, Riviere G, Steffensen I-L, Tlustos C, Van Loveren H, Vernis L, Zorn H, Glandorf B, Marcon F, Penninks A, Smith A, Gomes A, Kovalkovicova N, Liu Y, Maia J, Engel KH and Chesson A, 2019. Scientific Opinion on the safety evaluation of the food enzyme lysophospholipase from Trichoderma reesei (strain RF7206). EFSA Journal 2019;17(1):5548, 13 pp. https://doi.org/10.2903/j.efsa.2019.5548

ISSN: 1831-4732

© 2019 European Food Safety Authority. EFSA Journal published by John Wiley and Sons Ltd on behalf of European Food Safety Authority.

This is an open access article under the terms of the Creative Commons Attribution-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited and no modifications or adaptations are made.

The EFSA Journal is a publication of the European Food Safety Authority, an agency of the European Union.
## Table of contents

| Section                                                                 | Page |
|------------------------------------------------------------------------|------|
| Abstract                                                               | 1    |
| 1. Introduction                                                        | 4    |
| 1.1. Background and Terms of Reference as provided by the requestor   | 4    |
| 1.1.1. Background as provided by the European Commission             | 4    |
| 1.1.2. Terms of Reference                                              | 5    |
| 1.2. Interpretation of the Terms of Reference                         | 5    |
| 1.3. Information on existing authorisations and evaluations           | 5    |
| 2. Data and methodologies                                             | 5    |
| 2.1. Data                                                             | 5    |
| 2.2. Methodologies                                                    | 5    |
| 3. Assessment                                                         | 5    |
| 3.1. Source of the food enzyme                                         | 6    |
| 3.1.1. Characteristics of the parental and recipient microorganisms  | 6    |
| 3.1.2. Characteristics of the introduced sequences                    | 6    |
| 3.1.3. Description of the genetic modification process                | 6    |
| 3.1.4. Safety aspects of the genetic modification                     | 6    |
| 3.2. Production of the food enzyme                                     | 7    |
| 3.3. Characteristics of the food enzyme                               | 7    |
| 3.3.1. Properties of the food enzyme                                  | 7    |
| 3.3.2. Chemical parameters                                            | 7    |
| 3.3.3. Purity                                                         | 8    |
| 3.3.4. Viable cells and DNA of the production strain                  | 8    |
| 3.4. Toxicological data                                               | 8    |
| 3.4.1. Genotoxicity                                                   | 9    |
| 3.4.1.1. Bacterial reverse mutation test                             | 9    |
| 3.4.1.2. In vitro mammalian chromosomal aberration test               | 9    |
| 3.4.2. Repeated dose 90-day oral toxicity study in rodents            | 9    |
| 3.4.3. Allergenicity                                                 | 10   |
| 3.5. Dietary exposure                                                 | 11   |
| 4. Conclusions                                                        | 11   |
| Documentation provided to EFSA                                       | 11   |
| References                                                            | 11   |
| Abbreviations                                                         | 12   |
1. Introduction

Article 3 of the Regulation (EC) No 1332/2008 provides definitions for ‘food enzyme’ and ‘food enzyme preparation’.

‘Food enzyme’ means a product obtained from plants, animals or micro-organisms or products thereof including a product obtained by a fermentation process using microorganisms: (i) containing one or more enzymes capable of catalysing a specific biochemical reaction; and (ii) added to food for a technological purpose at any stage of the manufacturing, processing, preparation, treatment, packaging, transport or storage of foods.

‘Food enzyme preparation’ means a formulation consisting of one or more food enzymes in which substances such as food additives and/or other food ingredients are incorporated to facilitate their storage, sale, standardisation, dilution or dissolution.

Before January 2009, food enzymes other than those used as food additives were not regulated or were regulated as processing aids under the legislation of the Member States. On 20 January 2009, Regulation (EC) No 1332/2008 on food enzymes came into force. This Regulation applies to enzymes that are added to food to perform a technological function in the manufacture, processing, preparation, treatment, packaging, transport or storage of such food, including enzymes used as processing aids. Regulation (EC) No 1331/2008 established the European Union (EU) procedures for the safety assessment and the authorisation procedure of food additives, food enzymes and food flavourings. The use of a food enzyme shall be authorised only if it is demonstrated that:

i) it does not pose a safety concern to the health of the consumer at the level of use proposed;

ii) there is a reasonable technological need;

iii) its use does not mislead the consumer.

All food enzymes currently on the EU market and intended to remain on that market, as well as all new food enzymes, shall be subjected to a safety evaluation by the European Food Safety Authority (EFSA) and an approval via an EU Community list.

The ‘Guidance on submission of a dossier on a food enzyme for evaluation’ (EFSA CEF Panel, 2009) lays down the administrative, technical and toxicological data required.

1.1. Background and Terms of Reference as provided by the requestor

1.1.1. Background as provided by the European Commission

Only food enzymes included in the EU Community list may be placed on the market as such and used in foods, in accordance with the specifications and conditions of use provided for in Article 7 (2) of Regulation (EC) No 1332/2008 on food enzymes.

Five applications have been introduced by the companies “Danisco US Inc” for the authorisation of the food enzyme Hexose oxidase from a genetically modified strain of *Hansenula polymorpha* (strain DP-Jza21); “Novozymes A/S” for the authorisation of the food enzyme Pectin lyase from a genetically modified strain of *Aspergillus niger* (strain NZYM-PN); “Puratos NV” for the authorisation of the food enzyme Xylanase from a genetically modified strain of *Bacillus subtilis* (strain LMG-S-27588); the Association of Manufacturers and Formulators of Enzyme Products (AMFEP) for the authorisation of the food enzyme Beta-galactosidase from *Kluyveromyces lactis* and “AB Enzymes GmbH” for the authorisation of the food enzyme Lysophospholipase from a genetically modified strain of *Trichoderma reesei* (strain RF7206).

Following the requirements of Article 12.1 of Commission Regulation (EC) No 234/2011 implementing Regulation (EC) No 1331/2008, the Commission has verified that the five applications fall within the scope of the food enzyme Regulation and contain all the elements required under Chapter II of that Regulation.

---

1 Regulation (EC) No 1332/2008 of the European Parliament and of the Council of 16 December 2008 on Food Enzymes and Amending Council Directive 83/417/EEC, Council Regulation (EC) No 1493/1999, Directive 2000/13/EC, Council Directive 2001/112/EC and Regulation (EC) No 258/97. OJ L 354, 31.12.2008, p. 7–15.

2 Regulation (EC) No 1331/2008 of the European Parliament and of the Council of 16 December 2008 establishing a common authorisation procedure for food additives, food enzymes and food flavourings. OJ L 354, 31.12.2008, p. 1–6.

3 Commission Regulation (EU) No 234/2011 of 10 March 2011 implementing Regulation (EC) No 1331/2008 of the European Parliament and of the Council establishing a common authorisation procedure for food additives, food enzymes and food flavourings. OJ L 64, 11.3.2011, p. 15–24.
1.1.2. Terms of Reference

The European Commission requests the European Food Safety Authority to carry out the safety assessment on the food enzymes Hexose oxidase from a genetically modified strain of *Hansenula polymorpha* (strain DP-Jz2a21), Pectin lyase from a genetically modified strain of *Aspergillus niger* (strain NZYM-PN), Xylanase from a genetically modified strain of *Bacillus subtilis* (strain LMG-S-27588), Beta-galactosidase from *Kluyveromyces lactis* and Lysophospholipase from a genetically modified strain of *Trichoderma reesei* (strain RF7206) in accordance with the article 17.3 of Regulation (EC) No 1332/2008 on food enzymes.

1.2. Interpretation of the Terms of Reference

The present scientific opinion addresses the European Commission’s request to carry out the safety assessment of food enzyme lysophospholipase from a genetically modified *T. reesei* (strain RF7206).

1.3. Information on existing authorisations and evaluations

The applicant provides non-exhaustive lists of authorised enzymes (other than lysophospholipase) produced by the same production organism – *T. reesei*, and authorised lysophospholipase from production microorganisms other than *T. reesei*.

2. Data and methodologies

2.1. Data

The applicant has submitted a dossier in support of the application for authorisation of the food enzyme lysophospholipase from a genetically modified *T. reesei* (strain RF7206).

Additional information was sought from the applicant during the assessment process in requests from EFSA sent on 19 January 2018 and 16 October 2018 and was consequently provided (see ‘Documentation provided to EFSA’).

Following the request for additional data sent by EFSA on 19 January 2018, the applicant requested a clarification teleconference, which was held on 21 March 2018.

2.2. Methodologies

The assessment was conducted in line with the principles described in the EFSA ‘Guidance on transparency in the scientific aspects of risk assessment’ (EFSA, 2009) as well as in the EFSA ‘Scientific Opinion on Guidance on the risk assessment of genetically modified microorganisms and their products intended for food and feed use’ (EFSA GMO Panel, 2011) and following the relevant existing guidance of EFSA Scientific Committee.

The current ‘Guidance on the submission of a dossier on food enzymes for safety evaluation’ (EFSA CEF Panel, 2009) has been followed for the evaluation of the application with the exception of the exposure assessment, which was carried out in accordance to the methodology described in the CEF Panel statement on the exposure assessment of food enzymes (EFSA CEF Panel, 2016).

3. Assessment

IUBMB nomenclature: Lysophospholipase
Systematic name: 2-Lysophosphatidylcholine acylhydrolase
Synonyms: Lecithinase B
IUBMB No: EC 3.1.1.5
CAS No: 9001-85-8.

The lysophospholipase catalyses the hydrolysis of an ester bond between a fatty acid and glycerol in lysophospholipids, resulting in the formation of free fatty acids and glycerophosphatide. It is intended to be used in starch processing for the production of glucose syrups.
3.1. Source of the food enzyme

The lysophospholipase is produced with the genetically modified filamentous fungus \textit{T. reesei} strain RF7206 which is deposited in the Centraalbureau voor Schimmelcultures (CBS) with accession number CBS 125079.

3.1.1. Characteristics of the parental and recipient microorganisms

The parental strain is the \textit{T. reesei} strain RF7206.

The recipient strain \textit{T. reesei} was characterised by the CBS as \textit{T. reesei} on the basis of

3.1.2. Characteristics of the introduced sequences

The sequence encoding the

3.1.3. Description of the genetic modification process

The purpose of genetic modification was to enable the production strain to synthesise the enzyme lysophospholipase from \textit{T. reesei} RF7206.

The recipient strain \textit{T. reesei} was modified by

3.1.4. Safety aspects of the genetic modification

The technical dossier contains all necessary information on the recipient microorganism, the donor organism and the genetic modification process.

The production strain \textit{T. reesei} RF7206 differs from the recipient strain only in its capacity to produce the lysophospholipase enzyme from \textit{T. reesei}. The presence of the enzyme encoding gene was confirmed by Southern analysis. The phenotypic stability of the \textit{T. reesei} RF7206 strain was confirmed by its capacity to produce a constant level of the enzyme lysophospholipase measured in relation to the TOS in three independent batches of the food enzyme and its genetic stability was demonstrated by Southern analysis of samples taken after multiple (up to 10) generations grown in the absence of selective pressure.

No issues of concern arising from the genetic modifications were identified by the Panel.

---

4 Technical dossier/1st submission/Volume III.
5 Technical dossier/1st submission/Volume III/Appendix 3.
6 Technical dossier/1st submission/Volume III/Appendix 9.
7 Technical dossier/2nd submission/Enclosure 3.
8 Technical dossier/Additional data July 2018/Enclosure 3.
3.2. Production of the food enzyme

The food enzyme is manufactured according to the Food Hygiene Regulation (EC) No 852/2004, with food safety procedures based on Hazard Analysis and Critical Control Points (HACCP), and in accordance with current Good Manufacturing Practice (GMP).

The production strain is grown as a pure culture using a typical industrial medium in a submerged, fed-batch fermentation system with conventional process controls in place. After completion of the fermentation, the solid biomass is removed from the fermentation broth by filtration leaving a supernatant containing the food enzyme. The filtrate containing the enzyme is then further purified and concentrated. The applicant provided information on the identity and analysis of the substances used to control the fermentation and in the subsequent downstream processing of the food enzyme.

The Panel considered that sufficient information has been provided on the manufacturing process and the quality assurance system implemented by the applicant to exclude issues of concern.

3.3. Characteristics of the food enzyme

3.3.1. Properties of the food enzyme

The lysophospholipase is characterized by its molecular mass of the mature protein derived from the amino acid sequence (without the signal peptide) which was calculated to be \( M_r \). The protein pattern of the food enzyme was investigated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) analysis. Gels showed a major protein band of about \( M_r \), which is consistent with the calculated value for the lysophospholipase, and some minor protein bands of lower molecular mass. The food enzyme preparation was tested for xylanase, \( \beta \)-glucanase, and cellulase activities, which were determined to be \( X \). No other enzymatic side activities were reported.

The in-house determination of lysophospholipase activity is based on hydrolysis of the substrate lysolecithin (reaction conditions: pH 4.5, temperature 55°C, reaction time 10 min). The enzymatic activity is determined by measuring the release of fatty acids. The lysophospholipase activity is quantified relative to an enzyme standard and expressed in Lysophospholipase Units/g (LPL/g). One unit of lysophospholipase activity corresponds to the amount of enzyme which releases, in a 0.01 M lysolecithin-solution, 1 \( \mu \)mol fatty acids per minute at pH 4.5 and 55°C.

The food enzyme has been characterised with regard to its temperature and pH profiles. It has a temperature optimum around 65°C (pH 5.0) and a pH optimum between pH 4.0 and 5.5 (temperature 55°C). Thermostability was tested after incubation of the food enzyme at different temperatures. Under the conditions (pH 4.35) of the applied temperature stability assay, the lysophospholipase activity decreased rapidly above 65°C showing no residual activity after incubation at 85°C.

3.3.2. Chemical parameters

Data on the chemical parameters of the food enzyme preparation were provided for three batches to be used for commercialisation and one batch used for the toxicological tests (Table 1). The average total organic solids (TOS) of the three food enzyme batches for commercialisation was 7.8% (range 3.7–10.2%). The average enzyme activity/TOS ratio of the three food enzyme batches for commercialisation is 741.
3.3.3. Purity

The lead content in the three commercial batches and in the batch used for toxicological studies was below 0.05 mg/kg which complies with the specification for lead (< 5 mg/kg) as laid down in the general specifications and considerations for enzymes used in food processing (FAO/WHO, 2006).16

The food enzyme complies with the microbiological criteria as laid down in the general specifications and considerations for enzymes used in food processing (FAO/WHO, 2006), which stipulate that Escherichia coli and Salmonella species are absent in 25 g of sample and total coliforms should not exceed 30 colony forming unit (CFU) per gram. No antimicrobial activity was detected in any of these batches (FAO/WHO, 2006).17

The presence of mycotoxins (aflatoxins (B1, B2, G1 and G2), sterigmatocystin, ochratoxin A, deoxynivalenol, T2 toxin, HT-2 toxin, fumonisin (B1 and B2) and zearalenone) was examined in the four food enzyme preparation batches. The levels of these mycotoxins were found to be below the limits of detection.18

Strains of Trichoderma, in common with most filamentous fungi, have the capacity to produce a range of secondary metabolites (Blumenthal, 2004) including trichodermin (Watts et al., 1988). The applicant did not provide information on secondary metabolites, other than the mycotoxins indicated above, produced under the conditions of fermentation which might contribute to the food enzyme TOS. This issue is addressed by the toxicological examination of the food enzyme TOS.

The Panel considered that the information provided on the purity of the food enzyme is sufficient.

3.3.4. Viable cells and DNA of the production strain

The absence of the production strain in the food enzyme was demonstrated in three independent batches analysed in triplicate.19

A test for recombinant DNA in the food enzyme was made by polymerase chain reaction (PCR) analysis of three batches in triplicate. No DNA was detected.20

3.4. Toxicological data

A battery of toxicological tests including a bacterial gene mutation assay (Ames test), an in vitro mammalian chromosomal aberration test and a repeated dose 90-day oral toxicity study in rats has

---

16 Technical dossier/1st submission/Volume II/Annexes 1 and 2, Additional data July 2018. LOD = 0.05 mg/kg sample solution.
17 Technical dossier/1st submission/Volume II/Annexes 1 and 2, Additional data July 2018. LODs aflatoxins B1, B2, G1 and G2: 0.05 μg/kg each; sterigmatocystin: 10 μg/kg; ochratoxin A: 2 μg/kg; deoxynivalenol: 70 μg/kg; T2-toxin, HT-2-toxin: 20 μg/kg each; fumonisin B1 and B2: 10 μg/kg each; zearalenone: 50 μg/kg.
18 Technical dossier/Additional data July 2018/Enclosure 2.
19 Technical dossier/1st submission/Volume III/Appendices 6 and 20, and Additional data July 2018/Enclosure 4.
20 Technical dossier/Additional data July 2018/Enclosure 5 and November 2018.
been provided. The batch 4 (Table 1) used in these studies was a dried product with an activity/mg TOS comparable to the three batches for commercialisation. Its use is considered suitable for toxicological testing.

3.4.1. Genotoxicity

3.4.1.1. Bacterial reverse mutation test

A bacterial reverse mutation assay (Ames test) was made according to OECD Test Guideline 471 (OECD, 1997a) and following Good Laboratory Practice (GLP).  

Five strains of *Salmonella Typhimurium* (TA1535, TA1537, TA98, TA100 and TA102) were used in the presence or absence of metabolic activation, applying the direct plate incorporation method (experiment 1) and the pre-incubation method (experiment 2). The experiments were carried out in triplicate using the following amounts of the food enzyme: 3, 10, 33, 1,000, 2,500 and 5,000 µg/plate, corresponding to 2.7, 9.3, 31, 309, 927, 2,318 and 4,635 µg TOS/plate in the first experiment and 33, 100, 333, 1,000, 2,500 and 5,000 µg/plate, corresponding to 31, 93, 309, 927, 2,318 and 4,635 µg TOS/plate in the second experiment. No significant growth inhibition was observed in any strain at any dose level tested. Upon treatment with the food enzyme, there was no significant increase in the number of revertant colony numbers above the control values in any of the strains with or without S9-mix.

The Panel concluded that the food enzyme did not induce gene mutations under the test conditions employed in this study.

3.4.1.2. *In vitro* mammalian chromosomal aberration test

The *in vitro* mammalian chromosomal aberration test was carried out according to the OECD Test Guideline 473 (OECD, 1997b) and following GLP. Duplicate cultures of Chinese hamster V79 cells were treated with the food enzyme or appropriate positive controls, both in the presence and absence of metabolic activation. Two experiments were performed applying (i) a short-term treatment for 4 h followed by 14 h of recovery in the presence and absence of S9-mix (experiment 1); and (ii) a short-term treatment (4+14 h) with S9-mix and a continuous treatment (18+0 h) without S9-mix (experiment 2). Based on the results of a preliminary cytotoxicity test, the cells were treated with 1,250, 2,500 and 5,000 µg food enzyme/mL (corresponding to 1,159, 2,318 and 4,635 µg TOS/mL) in all the experimental conditions. Two hundred metaphases were scored per experimental point for the analysis of structural chromosomal aberrations. Neither precipitation in culture medium nor significant changes in osmolarity and pH were detected. No significant cytotoxicity was observed up to the highest concentration. In all the tested conditions, the frequency of cells with structural and numerical chromosomal aberrations in treated cultures was comparable to the values detected in the negative controls; exception was the statistically significant increase of aberrations (2%) observed after short treatment in the presence of S9-mix at 5,000 µg/mL (4,635 µg TOS/mL); however, this value was within the historical negative control range (0-4% aberrant cells, excluding gaps) and was not considered biologically relevant.

The Panel concluded that the food enzyme lysophospholipase did not induce structural and numerical chromosome aberrations in cultured Chinese hamster V79 cells, under the test conditions employed for this study.

3.4.2. Repeated dose 90-day oral toxicity study in rodents

The repeated dose 90-day oral toxicity study was performed in accordance with OECD Test Guideline 408 (OECD, 1998) and following GLP. Groups of 10 male and 10 female Wistar rats received via gavage the food enzyme in doses of 92.7, 278.1 or 927.0 mg TOS/kg body weight (bw) per day. Controls received the vehicle (water).

No mortality was observed. Kinked tail, transient hair loss and scabs in isolated rats without dose dependence were considered by the Panel as non-treatment related findings.

The mean daily feed intake in all treated male groups from days 15 to 22 onwards (except on days 29-43 in low-dose males) and in all treated female groups from days 36 to 43 onwards tended to be

---

21 Technical dossier/1st submission/Volume II/Annex 16.
22 Technical dossier/1st submission/Volume II/Annex 17.
lower than in the controls. As the differences to controls were small and the lower feed intake was not accompanied by changes in body weight, this finding was considered by the Panel of no toxicological significance.

The strength of the forelimb grip in all treated female groups and of the hind limb grip in mid-dose females were statistically significantly reduced compared to controls. The locomotor activity of high-dose males during the 20–30 min measurement interval was statistically significantly elevated as compared to that of controls. The Panel considered these findings to be of no toxicological relevance as they occurred without dose dependency and were limited to one sex.

Among haematological parameters, the only statistically significant difference to controls was an increased prothrombin time in low-dose females. In view of lacking dose dependency, occurrence in one sex only and that the value was within the range of historical control data from the laboratory, the Panel considered this finding as incidental.

Statistically significant differences to controls in clinical chemistry parameters for males included an increase in sodium (dose-related) and in calcium in all treated groups and increased chloride and cholesterol levels in the high-dose group. For females statistically significant differences included increased calcium in the low-dose group and increased urea, bilirubin and sodium in the high-dose group. As the changes in all the parameters (except for sodium in males) lacked the apparent dose–response, did not correlate with histopathology findings and all values were within the historical control ranges for the laboratory, the Panel considered these findings to be of no toxicological relevance.

Urinalysis revealed statistically significantly elevated urinary bilirubin in high-dose females. As this finding lacked dose–response relationship, consistency between sexes and the value was within the historical control range for the laboratory, the Panel considered this finding as not toxicologically relevant.

Analysis of organ weights revealed a statistically significantly lower absolute heart weight in high-dose males as compared to the controls, which, according to the Panel, could be explained by the (not statistically significant) lower body weights in this group (429 g vs 436 g in the control group).

In treated females, a statistically significantly lower mean absolute kidney weight and kidney-to-brain weight ratio in all treated groups and of kidney-to-body weight ratio in low- and high-dose groups were recorded. Additionally, statistically significantly lower uterus-to-brain ratio in the low-dose group and lower absolute and relative ovaries weights in the mid-dose group were recorded as compared to controls. The Panel considered the changes in organ weights of treated females to be of not toxicological relevance as these were not correlated with any histopathological changes and in case of kidneys with any functional changes (see urinalysis) and they were limited to one sex only.

No other effects were observed.

Overall, the Panel identified a no observed adverse effect level (NOAEL) of 927 mg TOS/kg bw per day, the highest dose tested.

3.4.3. Allergenicity

The allergenicity assessment considers only the food enzyme and not any carrier or other excipient which may be used in the final formulation.

The potential allergenicity of lysophospholipase produced with the genetically modified *T. reesei* strain RF7206 was assessed by comparison of its amino acid sequence with those of known allergens according to the scientific opinion on the assessment of allergenicity of GM plants and microorganisms and derived food and feed of the Scientific Panel on Genetically Modified Organisms (EFSA GMO Panel, 2017). Using higher than 35% identity in a sliding window of 80 amino acids as criterion, no match was found.

No information is available on oral sensitisation or elicitation reactions of this lysophospholipase. Several studies have shown that adults with occupational asthma may be able to ingest respiratory allergens without acquiring clinical symptoms of food allergy (Brisman, 2002; Poulsen, 2004; Armentia et al., 2009). In addition, no allergic reactions upon dietary exposure to any lysophospholipase have been reported in the literature. Therefore, it can be concluded that the likelihood of an allergic reaction upon oral ingestion of lysophospholipase produced with the genetically modified *T. reesei* strain RF7206, in individuals respiratory sensitised to lysophospholipase, cannot be excluded, but the likelihood of such a reaction to occur is considered to be low.

---

23 Technical dossier: Volume II, Annex 18.
According to the information provided, substances or products that may cause allergies or intolerances (Regulation EU 1169/2011) are used as raw materials in the growth medium of the production organism. However, during the fermentation process, these products will be degraded and utilised by the fungus for cell growth, cell maintenance and production of enzyme protein. In addition, the fungal biomass and fermentation solids will be removed. Considering the fermentation process and downstream processing, the Panel considered that potentially allergenic residues of these foods employed as protein sources are not expected to be present.

Quantifying the risk for allergenicity is not possible in view of the individual susceptibility to food allergens. Allergenicity can be ruled out only if the proteins are fully removed. In the starch processing for the production of glucose syrups, experimental data showed a significant removal (> 99%) of protein. However, traces of protein could be present in glucose syrup.

The Panel considered that, under the intended conditions of use, the risk of allergic sensitisation and elicitation reactions upon dietary exposure to this food enzyme cannot be excluded but the likelihood of such reactions to occur is considered to be low.

3.5. Dietary exposure

The lysophospholipase is intended to be used in starch processing for the production of glucose syrups at an intended use level of up to 1 mg TOS/kg starch.

In starch processing, the lysophospholipase is added after liquefaction, during the saccharification step, in order to remove the emulsifying properties of the lysophospholipids which are water-soluble and, thus, improve filtration rates.

Experimental data have been provided showing the removal (> 99%) of protein in the course of starch processing for the production of glucose syrups (Documentation provided to EFSA No 4). The Panel considered the evidence as sufficient to conclude that residual amounts of TOS (including substances other than proteins) are removed (> 99%) by the purification steps applied to the production of glucose syrups, i.e. filtration, ion exchange chromatography, treatment with active carbon.

As residual amounts of TOS are removed by the purification steps applied during the production of glucose syrups (by > 99%), a dietary exposure was not calculated.

4. Conclusions

Based on the data provided and on the removal of TOS during the intended food production process, the Panel concluded that the food enzyme lysophospholipase produced with the genetically modified T. reesei strain RF7206 does not give rise to safety concerns under the intended conditions of use.

The CEP Panel considers the food enzyme free from viable cells of the production organism and its recombinant DNA.

Documentation provided to EFSA

1) Dossier “Application for authorisation of a lysophospholipase from a genetically modified strain of Trichoderma reesei in accordance with Regulation (EC) No 1331/2008”, November 2015. Submitted by AB Enzymes GmbH.
2) Additional information was received from AB Enzymes in July 2018.
3) Additional information was received from AB Enzymes in November 2018.
4) Additional information on “Food enzyme removal during the production of cereal based distilled alcoholic beverages” and “Food enzyme carry-over in glucose syrups”. February 2017. Provided by the Association of Manufacturers and Formulators of Enzyme Products.

References

Armentia A, Días-Perales A, Castredoza J, Dueñas-Laita A, Palacin A and Fernández S, 2009. Why can patients with baker’s asthma tolerate wheat flour ingestion? Is wheat pollen allergy relevant? Allergologia et Immunopathologia, 37, 203-204.

24 Regulation (EU) No 1169/2011 of the European Parliament and of the Council of 25 October 2011 on the provision of food information to consumers, amending Regulations (EC) No 1924/2006 and (EC) No 1925/2006 of the European Parliament and of the Council, and repealing Commission Directive 87/250/EEC, Council Directive 90/496/EEC, Commission Directive 1999/10/EC, Directive 2000/13/EC of the European Parliament and of the Council, Commission Directives 2002/67/EC and 2008/5/EC and Commission Regulation (EC) No 608/2004.
Blumenthal CZ, 2004. Production of toxic metabolites in *Aspergillus niger*, *Aspergillus oryzae*, and *Trichoderma reesei*: justification of mycotoxin testing in food grade enzyme preparations derived from the three fungi. Regulatory Toxicology and Pharmacology, 39, 214–228.

Brisman J, 2002. Baker’s asthma. Occupational and Environmental Medicine, 59, 498–502; quiz 502, 426.

EFSA (European Food Safety Authority), 2009. Guidance of the Scientific Committee on Transparency in the Scientific Aspects of Risk Assessments carried out by EFSA. Part 2: general Principles. EFSA Journal 2009;7(5):1051, 22 pp. https://doi.org/10.2903/j.efsa.2009.1051

EFSA CEF Panel (EFSA Panel on Food Contact Material, Enzymes, Flavourings and Processing Aids), 2009. Guidance of EFSA prepared by the Scientific Panel of Food Contact Material, Enzymes, Flavourings and Processing Aids on the Submission of a Dossier on Food Enzymes. EFSA Journal 2009;7(8):1305, 1–26. https://doi.org/10.2903/j.efsa.2009.1305

EFSA CEF Panel (EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids), Silano V, Bolognesi C, Castle L, Cravedi J-P, Fowler P, Franz R, Grob K, Gürtler R, Husoy T, Karenlampi S, Mennes W, Milana MR, Penninks A, Smith A, Tavares Pocas MF, Tlustos C, Wolfe D, Zorn H, Zugravu C-A, Arcella D, Liu Y and Engel K-H, 2016. Panel statement on the exposure assessment of food enzymes. EFSA Journal 2016;14(11):4581, 9 pp. https://doi.org/10.2903/j.efsa.2016.4581

EFSA GMO Panel (EFSA Panel on Genetically Modified Organisms), 2011. Scientific Opinion on Guidance on the risk assessment of genetically modified microorganisms and their products intended for food and feed use. EFSA Journal 2011;9(6):2193, 54 pp. https://doi.org/10.2903/j.efsa.2011.2193

EFSA GMO Panel (EFSA Panel on Genetically Modified Organisms), Naegeli H, Birch AN, Casacuberta J, De Schrijver A, Gralak MA, Guerche P, Jones H, Manachini B, Messean A, Nielsen EE, Nogue F, Rogalić C, Rostoks N, Sweet J, Tebbe C, Viollet F, Wal J-M, Eigenmann P, Epstein M, Hoffmann-Sommergruber K, Koning F, Lovik M, Mills C, Moreno FJ, van Loveren H, Selb R and Fernandez-Dumont A, 2017. Guidance on allergenicity assessment of genetically modified plants. EFSA Journal 2017;15(5):4862, 49 pp. https://doi.org/10.2903/j.efsa.2017.4862

FAO/WHO (Food and Agriculture Organization of the United States/World Health Organization), 2006. General specifications and considerations for enzyme preparations used in food processing in Compendium of food additive specifications. 67th meeting. FAO JECFA Monographs 3, pp. 63–67. Available online: http://www.fao.org/3/a-a0675e.pdf

OECD (Organisation for Economic Co-operation and Development), 1997a. Bacterial Reverse Mutation Test. Guideline 471, adopted 21.07.1997. Available online: http://www.oecd-ilibrary.org/environment/test-no-471-bacterial-reverse-mutation-test_9789264071247-en;jsessionid=92f圭u35paaq.x-oecd-live-01

OECD (Organisation for Economic Co-operation and Development), 1997b. In vitro Mammalian Chromosomal Aberration Test. Guideline 473, adopted 21.07.1997. Available at http://www.oecd-ilibrary.org/environment/test-no-473-in-vitro-mammalian-chromosome-aberration-test_9789264071261-en

OECD (Organisation for Economic Co-operation and Development), 1998. Repeated Dose 90-day Oral Toxicity Study in Rodents. Guideline 408, adopted 21.09.1998. Available at http://www.oecd-ilibrary.org/environment/test-no-408-repeated-dose-90-day-oral-toxicity-study-in-rodents_9789264070707-en

Poulsen LK, 2004. Allergy assessment of foods or ingredients derived from biotechnology, gene-modified organisms, or novel food. Molecular Nutrition & Food Research, 48, 413–423.

Watts R, Dahiya J, Chandhary K and Tauro P, 1988. Isolation and characterization of a new antifungal metabolite of *Trichoderma reesei*. Plant and Soil, 107, 81–84.

Abbreviations

AMFEP Association of Manufacturers and Formulators of Enzyme Product
bw body weight
CAS Chemical Abstracts Service
CBS Centraalbureau voor Schimmelcultures
CEF EFSA Panel on Food Contact Material, Enzymes, Flavourings and Processing Aids
CEP EFSA Panel on Food Contact Materials, Enzymes and Processing Aids
CFU colony forming units
FAO Food and Agricultural Organization
GLP Good Laboratory Practice
GM genetically modified
GMO genetically modified organisms
GMP Good Manufacturing Practice
HACCP Hazard Analysis and Critical Control Points
IUBMB  International Union of Biochemistry and Molecular Biology
LPL    Lysophospholipase Units
NOAEL  no observed adverse effect level
OECD   Organisation for Economic Cooperation and Development
PCR    polymerase chain reaction
SDS-PAGE sodium dodecyl sulfate-poly acrylamide gel electrophoresis
TOS    total organic solids
WHO    World Health Organization